超广角荧光血管造影下阿柏西普治疗增殖性糖尿病视网膜病变的渗漏指数动态变化:RECOVERY研究
RECOVERY研究前瞻性纳入40只增殖性糖尿病视网膜病变眼,随机1:1接受阿柏西普2mg每4周或每12周治疗,用半自动渗漏分割平台分析超广角荧光血管造影。每4周组渗漏指数在24周和48周均显著下降至1.1%;每12周组24周改善不显著,48周显著降至1.4%;48周时两组渗漏指数相似。
要点
- 每4周阿柏西普组渗漏指数24周即显著降至1.1%,下降幅度79%。
- 每12周组24周改善不显著,48周显著降至1.4%,下降68%。
- 48周时两组渗漏指数相似,但每4周组下降更迅速。
核心结论
- 阿柏西普治疗增殖性糖尿病视网膜病变1年时渗漏指数显著降低。
- 每月给药比每季度给药更快速降低渗漏指数,但48周时两组渗漏指数相似。
研究设计与样本
- 前瞻性研究,将接受阿柏西普治疗的增殖性糖尿病视网膜病变受试者按1:1随机分配至2mg每4周组或每12周组。
- 共纳入40只眼(40名受试者),平均年龄48±12.1岁。
- 在基线、24周和48周获取超广角荧光血管造影图像,使用半自动渗漏分割平台分析,计算全视网膜及分区渗漏指数。
主要发现
- 每4周组平均注射次数为11±1.7次,每12周组为4±0.4次。
- 每4周组和每12周组基线渗漏指数中位数分别为5.1%和4.3%(P=0.28)。
- 每4周组24周和48周渗漏指数显著改善至1.1%(下降79%,P<0.0001)。
- 每12周组24周改善不显著(3.4%,下降21%,P=0.47),48周显著改善(1.4%,下降68%,P=0.02)。
- 24周时每4周组渗漏指数低于每12周组(1.1% vs 3.4%,P=0.008),48周时两组相似(1.1% vs 1.4%,P=0.34)。
临床怎么用
- 超广角荧光血管造影渗漏指数可作为评估增殖性糖尿病视网膜病变抗VEGF治疗反应的定量指标。
- 每月阿柏西普治疗可更快速降低渗漏指数,但每季度给药在48周时也可达到相似水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Characterization of leakage indices on ultra-widefield fluorescein angiography in proliferative diabetic retinopathy treated with intravitreal aflibercept. METHODS: Prospective study enrolling subjects for treatment of proliferative diabetic retinopathy randomized 1:1 to receive 2-mg intravitreal aflibercept every 4 weeks (2q4) or every 12 weeks (2q12). Ultra-widefield fluorescein angiography images obtained at baseline, 24, and 48 weeks were analyzed using a semiautomated leakage segmentation platform. Panretinal and zonal leakage indices were calculated. RESULTS: Forty eyes of 40 subjects were included, and mean age was 48 ± 12.1 years. Mean number of injections was 11 ± 1.7 in the 2q4 arm and 4 ± 0.4 in the 2q12 arm. Median baseline leakage index in the 2q4 and 2q12 groups was 5.1% and 4.3%, respectively (P = 0.28). At 24 and 48 weeks, the 2q4 group significantly improved to 1.1% (-79%, P < 0.0001). At Week 24, the 2q12 group demonstrated nonsignificant improvement (3.4%; -21%, P = 0.47); by Week 48, improvement was significant (1.4%; -68%, P = 0.02). The 2q4 group resulted in lower leakage index compared with the 2q12 group at 24 weeks (1.1% vs. 3.4%, respectively; P = 0.008), but by 48 weeks, leakage index was similar between both groups (1.1% vs. 1.4%, respectively; P = 0.34). CONCLUSION: Proliferative diabetic retinopathy treated with intravitreal aflibercept demonstrated significant leakage index reductions at 1 year. Monthly dosing provided more rapid reduction in leakage index compared with quarterly dosing. TRIAL REGISTRATION: RECOVERY study (NCT02863354); https://clinicaltrials.gov/ct2/show/NCT02863354.
引用
- Babiuch AS, Wykoff CC, Srivastava SK, et al. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. Retina. 2020. PMID: 31917731. doi:10.1097/IAE.0000000000002727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。